$16 Billion Market for Infectious Disease Testing

January 27, 2016 Genetic Engineering & Biotechnology News sites Cavidi technology as a novel approach to addressing the challenges of microbial resistance that is on the rise. Healthcare is now looking to testing and monitoring to halt the global surge of bacterial infection.  

"Leveraging immunodiagnostics to perform viral load testing is not common, but has been developed by Cavidi with its near-patient ELISA-format ExaVir™ system. The ExaVir system and several portable molecular systems introduced in recent years are intended to address HIV therapy in the developing world, where ruggedness, low-cost reagents (including non-PCR) and non-molecular methodologies remain preferred features in markets where improved testing platform performance needs to be achieved at significantly reduced costs."

http://www.genengnews.com/